MISSION

The Group is focused on improving outcomes for adult patients with leukemias or related hematologic malignancies (blood cancers). Members operate clinical trials, including large standard-practice changing phase III studies. The Group also develops robust survivorship studies, taking advantage of the large number of patients already included in phase III research.

PRACTICE CHANGING RESEARCH

  • Leukemia Group / Elderly

    EORTC 06012 – Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 – 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC – LG and the GIMEMA-ALWP.

    EORTC found that the addition of gentuzumab ozogamicin (GO) prior to standard induction treatment provides no benefit for patients of 61 to 75 years old with acute myelogenous leukemia (AML).

    READ MORE

  • Leukemia Group

    EORTC 06991 – The value of high dose versus standard dose Ara-c during induction and IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 yrs) with acute myelogenous leukemia.

    A randomized phase III trial of the EORTC and GIMEMA Leukemia Cooperative Groups (AML-12).

    EORTC found higher doses of chemotherapy drug cytarabine during first phase treatment, provided higher response and survival rates than the standard dose, in acute myelogenous leukemia (AML) patients, especially if younger than 46 years old.

    READ MORE

  • Leukemia Group / Elderly

    EORTC 06011 – Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10% blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for intensive therapy.

    An EORTC-German MDS Study Group randomized phase III study.

    This EORTC study established the efficacy and safety of treatment with decitabine, in elderly patients with higher-risk Myelodysplastic Syndrome (MDS).

    READ MORE

  • Leukemia Group

    EORTC / GIMEMA 060661 – Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)

    EORTC and GIMEMA found the addition of clofarabine to the standard first-phase treatment lead to higher response rates and prolonged survival in patients with intermediate/high-risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).

    READ MORE

  • Leukemia Group

    EORTC 06031 – Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP.

    EORTC found that low-dose of gentuzumab ozogamicin (GO), compared with best supportive care, prolonged survival without serious adverse effects in elderly patients with acute myelogenous leukemia (AML), who were ineligible for intensive chemotherapy.

    READ MORE

  • Leukemia Group

    EORTC 06863 – A randomized phase III study of autologous bone marrow transplantation versus intensive consolidation during first complete remission in acute myelogenous leukemia (AML-8A).

    EORTC published the final, long-term follow-up results of the AML-8A study, which began in 1995. Results confirmed the efficacy of bone marrow transplant, compared to intensive chemotherapy, in improving disease-free survival in younger adult patients with acute myelogenous leukemia (AML) after complete remission.

    READ MORE

  • Oct-13
  • Jan-14
  • Dec-15
  • Feb-16
  • Mar-16
  • Jan-20

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up